These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10720858)

  • 1. Detrusor contraction duration may predict response to alpha-blocker therapy for lower urinary tract symptoms.
    Kaplan SA; Stifelman M; Avillo C; Reis RB; Te AE
    Eur Urol; 2000 Mar; 37(3):314-7. PubMed ID: 10720858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of novel urodynamic parameters, detrusor contraction duration and detrusor contraction index, in men with lower urinary tract symptoms.
    Turner CD; Kuznetsov D; Contreras BA; Gerber GS
    Tech Urol; 1998 Sep; 4(3):136-40. PubMed ID: 9800891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Urodynamic criteria of predicting efficacy of therapy with alpha1-adrenergic blockaders in patients with benign prostatic hyperplasia].
    Sivkov AV; Egorov AA; Romikh VV; Surikov VN
    Urologiia; 2002; (5 Suppl):13-22. PubMed ID: 12518669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of doxazosin efficacy in the treatment of the benign prostatic enlargement].
    Aganović D; Aganović K; Prcić A
    Med Arh; 2004; 58(3):153-6. PubMed ID: 15484855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ambulatory urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
    Gerber GS; Contreras BA; Rukstalis DB
    Tech Urol; 1997; 3(3):164-7. PubMed ID: 9422449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
    Gerber GS; Kim JH; Contreras BA; Steinberg GD; Rukstalis DB
    Urology; 1996 Jun; 47(6):840-4. PubMed ID: 8677574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxazosin in men with lower urinary tract symptoms: urodynamic evaluation at 15 months.
    Gerber GS; Contreras BA; Zagaja GP; Kim JH; Steinberg GD; Rukstalis DB
    Urology; 1997 Aug; 50(2):229-33. PubMed ID: 9255293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detrusor contraction duration as a urodynamic parameter of bladder outlet obstruction for evaluating men with lower urinary tract symptoms.
    Ameda K; Steele GS; Sullivan MP; Stember D; Yalla SV
    J Urol; 1998 Aug; 160(2):482-6. PubMed ID: 9679903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change in parameters before and after alpha-1-blocker therapy for men with lower urinary tract symptoms using color doppler ultrasound urodynamics: possible application for prediction of clinical outcome.
    Watanabe Y; Yokoyama T; Ozawa H; Nishiguchi J; Nose H; Kumon H
    Urol Int; 2004; 73(3):252-7. PubMed ID: 15539846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant correlation of the American Urological Association symptom score and a novel urodynamic parameter: detrusor contraction duration.
    Kaplan SA; Reis RB
    J Urol; 1996 Nov; 156(5):1668-72. PubMed ID: 8863567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms.
    Ozdemir I; Bozkurt O; Demir O; Aslan G; Esen AA
    Urology; 2009 Aug; 74(2):431-5. PubMed ID: 19501883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?
    Barendrecht MM; Abrams P; Schumacher H; de la Rosette JJ; Michel MC
    Neurourol Urodyn; 2008; 27(3):226-30. PubMed ID: 17638312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The doxazosin treatment of the changes in the bladder filling phase in benign prostatic hyperplasia].
    Salinas Casado J; Esteban Fuertes M; Virseda Chamorro M; Ramírez Fernández JC; Salomón Moh'd S; Luengo Alpuente S; Resel Estévez L
    Arch Esp Urol; 1997 Oct; 50(8):840-5. PubMed ID: 9463281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urodynamic effects of doxazosin in men with lower urinary tract symptoms and benign prostatic obstruction. Results from three double-blind placebo-controlled studies.
    Abrams P
    Eur Urol; 1997; 32(1):39-46. PubMed ID: 9266230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.
    Kaplan SA; He W; Koltun WD; Cummings J; Schneider T; Fakhoury A
    Eur Urol; 2013 Jan; 63(1):158-65. PubMed ID: 22831853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
    de Reijke TM; Klarskov P
    BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of doxazosin in men with benign prostatic hyperplasia: urodynamic assessment.
    Ozbey I; Aksoy Y; Polat O; Biçgi O; Demirel A; Okyar G
    Int Urol Nephrol; 1999; 31(4):471-9. PubMed ID: 10668942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urodynamic effects of alpha1-blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder.
    Kakizaki H; Ameda K; Kobayashi S; Tanaka H; Shibata T; Koyanagi T
    Int J Urol; 2003 Nov; 10(11):576-81. PubMed ID: 14633081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms.
    Kaplan SA; Reis RB; Cologna A; Suaid HJ; Martins AC; Kohn IJ; Te AE
    Urology; 1998 Jul; 52(1):12-6. PubMed ID: 9671862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.